Lifeward (NASDAQ:LFWD) Releases Earnings Results, Misses Estimates By $5.52 EPS

Lifeward (NASDAQ:LFWD) posted its quarterly earnings data on Friday, May 15th. The company reported ($6.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($5.52), Zacks reports. The company had revenue of $3.92 million for the quarter, compared to analyst estimates of $5.78 million. Lifeward had a negative net margin of 123.66% and a negative return on equity of 243.14%.

Here are the key takeaways from Lifeward’s conference call:

• Lifeward completed the Oratech acquisition, which management says expands the company into a more diversified biomedical innovation platform and gives shareholders exposure to the oral protein delivery technology with limited near-term operating burden.
• The company raised $10 million through convertible note financing and added cash from the transaction, ending Q1 2026 with $11.4 million in unrestricted cash versus $2.2 million at year-end 2025.
• First-quarter revenue fell to $3.9 million from $5.0 million, mainly because AlterG shipments were delayed by manufacturing, sourcing, and working capital issues during the transition to contract manufacturing.
• ReWalk personal exoskeleton revenue rose 11% year over year to $1.6 million, helped by reimbursement progress, distribution expansion, and stronger international sales, including nearly 25% growth in Germany.
• Management expects AlterG shipments to improve in the second and third quarters as backlog is worked down, and reiterated that 2026 revenue should be similar to 2025 despite a weak first quarter.

Lifeward Price Performance

Shares of NASDAQ:LFWD opened at $8.45 on Wednesday. The company has a 50-day simple moving average of $7.13 and a 200-day simple moving average of $7.04. Lifeward has a one year low of $4.14 and a one year high of $10.98. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.82 and a current ratio of 2.40. The stock has a market capitalization of $23.74 million, a price-to-earnings ratio of -0.43 and a beta of 0.37.

Hedge Funds Weigh In On Lifeward

Institutional investors have recently added to or reduced their stakes in the stock. HRT Financial LP boosted its holdings in shares of Lifeward by 149.7% in the fourth quarter. HRT Financial LP now owns 49,081 shares of the company’s stock valued at $28,000 after acquiring an additional 29,423 shares in the last quarter. Virtu Financial LLC raised its holdings in Lifeward by 158.0% during the fourth quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after purchasing an additional 37,037 shares in the last quarter. Jane Street Group LLC raised its holdings in Lifeward by 77.3% during the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after purchasing an additional 29,927 shares in the last quarter. Finally, Citadel Advisors LLC lifted its position in Lifeward by 1,271.8% in the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after purchasing an additional 198,406 shares during the period. Institutional investors and hedge funds own 26.76% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on LFWD shares. Weiss Ratings restated a “sell (e+)” rating on shares of Lifeward in a report on Tuesday, April 21st. HC Wainwright increased their price target on shares of Lifeward to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Finally, Zacks Research lowered shares of Lifeward from a “hold” rating to a “strong sell” rating in a report on Wednesday, June 3rd. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $10.00.

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.